Home » Newsletters » BioWorld Science

BioWorld Science

Nov. 25, 2019

View Archived Issues

Study shows TINCR lncRNA overexpression in epithelial ovarian cancer and role in tumor progression

Upadacitinib demonstrates promising safety and efficacy in phase II/III SELECT-AXIS 1 study

Hepatic YBX1 as a novel therapeutic target for obesity-related liver disorders

Klotho shows potential as therapeutic target in podocyte injury of diabetic nephropathy

Phase I data presented for TPI-287 in Alzheimer's disease and 4-repeat tauopathies

CLCA1-TMEM16A-chloride current pathway mediates renal injury in aging and diabetes

Discovery of targetable dopamine receptor controlling childhood-onset asthma

NASH progression tied to redox state

Leptin affects T-cell metabolism

New pan alphav antagonist with excellent oral PK properties and bioavailability for IPF treatment

Amgen discovers KRAS G12C inhibitors

New RIP-1 inhibitors identified at Rigel Pharmaceuticals

Shanghai Longwood Biopharmaceuticals patents HBV caspid assembly inhibitors

Medshine Discovery describes new HER2 inhibitors

Johnson & Johnson identifies new anti-HBV compounds

Neuraly studies NLY-01 in phase II for type 2 diabetes

Clinical data presented for AT-001 in patients with T2D-derived diabetic cardiomyopathy

Oyster Point Pharma reports topline phase I results with OC-01 nasal spray for dry eye

EI-1071 to enter phase I testing next year

Dynamin-2 is upregulated in pulmonary arterial hypertension

AKCEA-TTR-LRx begins phase III trial for polyneuropathy caused by hATTR amyloidosis

New phase III trial evaluates oral formulation of edaravone for ALS

Soliris approved in Japan for neuromyelitis optica spectrum disorder

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for Dec. 31, 2025.
Today's news in brief
BioWorld MedTech
BioWorld MedTech briefs for Dec. 31, 2025.
Shionogi nabs revenue-generating ALS drugs with $2.5B Tanabe pact
BioWorld
Shionogi & Co. Ltd. will acquire global rights to U.S. FDA approved amyotrophic lateral sclerosis therapy edaravone through a $2.5 billion acquisition deal with...
Big pharma taps fast Asia innovation in search of next Keytruda
BioWorld
Speed and innovation from Asia Pacific’s (APAC) biotechnology sector had big pharma scouring the region for the next oncology heir to Keytruda (pembrolizumab),...
IMV-101 shows promise for B-cell malignancies
BioWorld Science
IMV-101 is a new CAR T-cell therapy targeting CD19 developed by Suzhou Immunofoco Biotechnology Co. Ltd. for the potential treatment of B-cell malignancies and...